123 related articles for article (PubMed ID: 15060446)
21. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
22. Atazanavir: clinical use.
Bartlett JG
Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
[No Abstract] [Full Text] [Related]
23. Atazanavir and chest pain.
Phillips M; Saxon C; Lee V
Int J STD AIDS; 2014 May; 25(6):461-4. PubMed ID: 24108452
[TBL] [Abstract][Full Text] [Related]
24. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future?
TreatmentUpdate; 2003; 15(3):5-6. PubMed ID: 17219613
[No Abstract] [Full Text] [Related]
25. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
26. PI monotherapy effective as maintenance.
AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
[No Abstract] [Full Text] [Related]
27. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
28. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
29. Report from the 13th retrovirus conference. Extending the role of atazanavir.
Feinberg J
AIDS Clin Care; 2006 Apr; 18(4):38. PubMed ID: 16718882
[No Abstract] [Full Text] [Related]
30. Drug profile: atazanavir (Reyataz, ATV).
Pham PA
Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
[No Abstract] [Full Text] [Related]
31. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Vora S; Marcelin AG; Günthard HF; Flandre P; Hirsch HH; Masquelier B; Zinkernagel A; Peytavin G; Calvez V; Perrin L; Yerly S;
AIDS; 2006 Jan; 20(1):35-40. PubMed ID: 16327317
[TBL] [Abstract][Full Text] [Related]
32. Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
TreatmentUpdate; 2008 Mar; 20(2):7-8. PubMed ID: 18661646
[No Abstract] [Full Text] [Related]
33. Lipodystrophy is associated with a low rate of treatment failure in HIV-positive patients switched to atazanavir.
Zaccarelli M; Zinzi D; Trotta MP; Liuzzi G; Sette P; Marconi P; Acinapura R; Antinori A
J Acquir Immune Defic Syndr; 2005 May; 39(1):125-6. PubMed ID: 15851923
[No Abstract] [Full Text] [Related]
34. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
35. Anti-HIV agents. Atazanavir vs. Kaletra.
TreatmentUpdate; 2005; 17(1):3-4. PubMed ID: 17225314
[No Abstract] [Full Text] [Related]
36. Atazanavir: a review of its use in the management of HIV infection.
Swainston Harrison T; Scott LJ
Drugs; 2005; 65(16):2309-36. PubMed ID: 16266202
[TBL] [Abstract][Full Text] [Related]
37. Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
Petersen K; Riddle MS; Jones LE; Furtek KJ; Christensen AR; Tasker SA; Hale BR
AIDS; 2005 Oct; 19(15):1700-2. PubMed ID: 16184044
[TBL] [Abstract][Full Text] [Related]
38. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
39. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Jan; 19(2):153-62. PubMed ID: 15668540
[No Abstract] [Full Text] [Related]
40. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
Sax PE
J Watch AIDS Clin Care; 2009 Oct; 21(10):80. PubMed ID: 20458811
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
